Clinical trial
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
NCT00357630 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00357630 |
|---|---|
| Title | Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary |
| Official title | Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma of Unknown Primary, Pain |
| Intervention type | Drug, Procedure |
| Interventions | gemcitabine hydrochloride, quality-of-life assessment |
| Enrollment | 52 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2007 |
| First posted | Jul 27, 2006 |
| Last update posted | Nov 2, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: